SurModics says Merck drops it as partner
By
Associated Press
September 17, 2008
|
SurModics Inc., which makes products to deliver pharmaceuticals to patients, said Wednesday Merck & Co. plans to stop a collaboration agreement the two signed in 2007.
The Eden Prairie, Minn., company said the move triggers a $9 million payment to SurModics. Merck's decision was not based on the safety of SurModics products, the company said.
The two were exploring the safety and effectiveness of SurModics' I-vation TA system for delivering eye medication.
Under the original deal, announced in 2007, SurModics was to receive an upfront licensing fee of $20 million and be eligible for fees up to $288 million for providing the I-vation system.
SurModics shares slumped $6.31, or 16 percent, to $32.80 in electronic aftermarket trading. The stock's 52-week range is $36.25 to $56.75. It closed Wednesday at $39.11.